Carisma Common Stock Shares Outstanding vs Cash And Short Term Investments Analysis

CARM Stock   0.56  0.13  18.84%   
Carisma Therapeutics financial indicator trend analysis is way more than just evaluating Carisma Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Carisma Therapeutics is a good investment. Please check the relationship between Carisma Therapeutics Common Stock Shares Outstanding and its Cash And Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.

Common Stock Shares Outstanding vs Cash And Short Term Investments

Common Stock Shares Outstanding vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Carisma Therapeutics Common Stock Shares Outstanding account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong relationship.
The correlation between Carisma Therapeutics' Common Stock Shares Outstanding and Cash And Short Term Investments is 0.72. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Carisma Therapeutics, assuming nothing else is changed. The correlation between historical values of Carisma Therapeutics' Common Stock Shares Outstanding and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Carisma Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Common Stock Shares Outstanding i.e., Carisma Therapeutics' Common Stock Shares Outstanding and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.72
Relationship DirectionPositive 
Relationship StrengthSignificant

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Carisma Therapeutics balance sheet. This account contains Carisma Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Carisma Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Carisma Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Carisma Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.As of the 11th of December 2024, Selling General Administrative is likely to grow to about 31 M, while Issuance Of Capital Stock is likely to drop about 24 M.
 2021 2022 2023 2024 (projected)
Interest Expense8.3M3.1M1.9M2.0M
Depreciation And Amortization85K6.1M2.8M3.0M

Carisma Therapeutics fundamental ratios Correlations

0.120.560.430.180.13-0.58-0.820.310.610.780.10.640.260.830.610.750.830.650.30.110.26-0.58-0.340.02-0.12
0.120.650.71-0.570.560.38-0.12-0.03-0.02-0.090.180.24-0.20.290.15-0.190.350.24-0.250.340.66-0.08-0.31-0.09-0.41
0.560.650.91-0.530.68-0.1-0.680.270.350.240.10.540.280.710.680.30.770.560.150.690.62-0.67-0.74-0.2-0.67
0.430.710.91-0.410.8-0.17-0.590.490.46-0.020.040.650.410.490.530.240.570.660.080.530.83-0.59-0.76-0.07-0.73
0.18-0.57-0.53-0.41-0.31-0.590.060.270.410.11-0.190.220.26-0.35-0.450.34-0.370.190.18-0.5-0.240.00.170.250.26
0.130.560.680.8-0.31-0.13-0.30.490.4-0.28-0.180.580.580.150.280.00.240.580.130.610.69-0.63-0.870.12-0.89
-0.580.38-0.1-0.17-0.59-0.130.64-0.67-0.93-0.140.15-0.8-0.74-0.24-0.38-0.77-0.25-0.79-0.450.12-0.150.590.38-0.210.17
-0.82-0.12-0.68-0.590.06-0.30.64-0.32-0.72-0.49-0.23-0.74-0.57-0.82-0.77-0.87-0.84-0.76-0.25-0.2-0.490.720.560.230.37
0.31-0.030.270.490.270.49-0.67-0.320.72-0.22-0.440.70.620.030.350.230.080.690.440.180.28-0.49-0.520.46-0.42
0.61-0.020.350.460.410.4-0.93-0.720.720.05-0.10.960.760.330.440.740.360.960.370.010.43-0.68-0.560.19-0.39
0.78-0.090.24-0.020.11-0.28-0.14-0.49-0.220.050.220.04-0.160.730.330.510.680.050.12-0.01-0.14-0.210.07-0.150.23
0.10.180.10.04-0.19-0.180.15-0.23-0.44-0.10.22-0.06-0.040.340.020.370.32-0.05-0.85-0.450.160.270.28-0.650.25
0.640.240.540.650.220.58-0.8-0.740.70.960.04-0.060.720.420.50.660.471.00.310.150.58-0.72-0.660.17-0.52
0.26-0.20.280.410.260.58-0.74-0.570.620.76-0.16-0.040.720.10.280.580.140.710.220.130.44-0.68-0.72-0.01-0.61
0.830.290.710.49-0.350.15-0.24-0.820.030.330.730.340.420.10.810.620.990.450.10.240.28-0.48-0.29-0.22-0.13
0.610.150.680.53-0.450.28-0.38-0.770.350.440.330.020.50.280.810.470.820.540.370.40.26-0.56-0.43-0.01-0.27
0.75-0.190.30.240.340.0-0.77-0.870.230.740.510.370.660.580.620.470.610.670.08-0.220.29-0.51-0.28-0.27-0.08
0.830.350.770.57-0.370.24-0.25-0.840.080.360.680.320.470.140.990.820.610.50.10.290.36-0.52-0.36-0.22-0.21
0.650.240.560.660.190.58-0.79-0.760.690.960.05-0.051.00.710.450.540.670.50.320.170.58-0.73-0.670.16-0.52
0.3-0.250.150.080.180.13-0.45-0.250.440.370.12-0.850.310.220.10.370.080.10.320.51-0.11-0.55-0.430.43-0.3
0.110.340.690.53-0.50.610.12-0.20.180.01-0.01-0.450.150.130.240.4-0.220.290.170.510.2-0.64-0.710.1-0.67
0.260.660.620.83-0.240.69-0.15-0.490.280.43-0.140.160.580.440.280.260.290.360.58-0.110.2-0.41-0.6-0.11-0.61
-0.58-0.08-0.67-0.590.0-0.630.590.72-0.49-0.68-0.210.27-0.72-0.68-0.48-0.56-0.51-0.52-0.73-0.55-0.64-0.410.85-0.190.64
-0.34-0.31-0.74-0.760.17-0.870.380.56-0.52-0.560.070.28-0.66-0.72-0.29-0.43-0.28-0.36-0.67-0.43-0.71-0.60.850.030.94
0.02-0.09-0.2-0.070.250.12-0.210.230.460.19-0.15-0.650.17-0.01-0.22-0.01-0.27-0.220.160.430.1-0.11-0.190.030.16
-0.12-0.41-0.67-0.730.26-0.890.170.37-0.42-0.390.230.25-0.52-0.61-0.13-0.27-0.08-0.21-0.52-0.3-0.67-0.610.640.940.16
Click cells to compare fundamentals

Carisma Therapeutics Account Relationship Matchups

Carisma Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets114.4M58.5M35.4M72.2M89.6M65.7M
Other Current Liab6.6M1.6M4.5M10.9M6.7M4.1M
Total Current Liabilities8.5M5.7M7.7M19.7M15.9M8.0M
Total Stockholder Equity(26.7M)35.8M11.6M(49.3M)26.5M27.9M
Property Plant And Equipment Net238K5.2M5.7M13.5M8.9M9.4M
Net Debt(48.1M)(48.3M)(25.9M)16.0M(74.5M)(70.8M)
Retained Earnings(293.5M)(56.2M)(97.0M)(158.2M)(245.1M)(232.8M)
Accounts Payable1.9M3.3M2.3M1.7M3.9M2.1M
Cash48.1M51.8M28.6M24.2M77.6M81.5M
Non Current Assets Total59.9M5.4M5.7M17.6M9.1M8.6M
Non Currrent Assets Other196K(78.5M)(84.9M)4.1M146K153.3K
Cash And Short Term Investments48.1M51.8M28.6M52.0M77.6M81.5M
Common Stock Shares Outstanding4.5M5.9M9.1M106.4K33.5M35.2M
Liabilities And Stockholders Equity114.4M58.5M35.4M72.2M89.6M65.7M
Non Current Liabilities Total132.5M2.6M1.7M81.6M47.1M39.8M
Other Current Assets6.3M1.3M1.2M2.6M2.9M1.5M
Other Stockholder Equity266.8M199K619K1.2M271.6M285.2M
Total Liab141.1M8.3M9.4M101.3M63.0M47.8M
Total Current Assets54.4M53.1M29.8M54.6M80.5M84.5M
Accumulated Other Comprehensive Income(758K)(140K)(199K)(41K)(89.6M)(85.1M)
Common Stock77K107K140K199K40K56.4K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Carisma Therapeutics is a strong investment it is important to analyze Carisma Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Carisma Therapeutics' future performance. For an informed investment choice regarding Carisma Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.52)
Revenue Per Share
0.493
Quarterly Revenue Growth
(0.12)
Return On Assets
(0.56)
Return On Equity
(3.63)
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.